Other Asia comprises all Asian territories excluding China and Japan. Anaesthetics make up 46% of revenue in these countries, followed by several products in the Regional Brands category. We have active trading subsidiaries in the Philippines, Taiwan and Malaysia.
Key Countries and Territories
Contribution to Group revenue
Revenue contribution - by therapeutic category
- The Asian pharmaceutical sector (excluding China and Japan) grew 7,7% and was valued at USD57 billion as at 31 December 2017.
- The pharmaceutical sectors in Hong Kong, Philippines and Singapore (which are Aspen’s key countries in “Other Asia”) grew 10,0%, 1,7% and 5,3% respectively for the year ended 31 December 2017.
Source: December 2017 IMS
Number of products launched:
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
3 – 5 years
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
|Revenue – R’billion||2018||2017 (CER)||% change|
|Total||1 401||1 148||22|
|High Potency & Cytotoxics||262||246||7|